[High-dosage chemotherapy with support of autologous haematopoietic cells in the treatment of multiple myeloma--review of contemporary possibilities].
High-dosage chemotherapy with autologous transplantation of haematopietic stem cells prolonged the survival of patients with multiple myeloma as compared with results of standard chemotherapy, on average by 1.5 years. Nowadays this method is the standard treatment for suitable patients. Findings assembled recently are discussed by the authors.
Rácil
Z
Z
Interni hematoonkologická klinika FN Brno.
Adam
Z
Z
Hájek
R
R
Tomíska
M
M
Krejcí
M
M
Krivanová
A
A
Höklová
J
J
Doubek
M
M
Mayer
J
J
Vorlícek
J
J
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents